RLAY (Relay Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RLAY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-28 | Peter Rahmer | See remarks | Sell | — | — |
| 2026-08-28 | SVF Pauling (Cayman) Ltd | 10%+ Owner | Sell | — | — |
| 2026-08-18 | Thomas Catinazzo | Chief Financial Officer | Sell | — | — |
| 2026-08-18 | Sanjiv Patel | President and CEO | Sell | — | — |
| 2026-07-30 | Donald A Bergstrom | President, R&D | Sell | — | — |
| 2026-07-30 | Peter Rahmer | See remarks | Sell | — | — |
| 2026-07-30 | Thomas Catinazzo | Chief Financial Officer | Sell | — | — |
| 2026-07-08 | Sanjiv Patel | President and CEO | MIXED | — | — |
| 2026-07-08 | Thomas Catinazzo | Chief Financial Officer | Sell | — | — |
| 2026-07-08 | Donald A Bergstrom | President, R&D | Sell | — | — |
| 2026-07-02 | Peter Rahmer | See remarks | MIXED | — | — |
| 2026-06-24 | Donald A Bergstrom | President, R&D | MIXED | — | — |
| 2026-06-24 | Thomas Catinazzo | Chief Financial Officer | MIXED | — | — |
| 2026-06-10 | Claire Mazumdar | Director | A | — | — |
| 2026-06-10 | DOUGLAS S INGRAM | Director | A | — | — |
| 2026-06-10 | LONNEL COATS | Director | A | — | — |
| 2026-06-10 | LINDA A HILL | Director | A | — | — |
| 2026-06-10 | Habib J Dable | Director | A | — | — |
| 2026-06-10 | Alexis Borisy | Director | A | — | — |
| 2026-06-10 | Mark Murcko | Director | A | — | — |
| 2026-05-14 | Thomas Catinazzo | Chief Financial Officer | Sell | — | — |
| 2026-04-09 | Thomas Catinazzo | Chief Financial Officer | MIXED | — | — |
| 2026-03-11 | Thomas Catinazzo | Chief Financial Officer | Sell | — | — |
| 2026-01-29 | Peter Rahmer | See remarks | MIXED | — | — |
| 2026-01-29 | Donald A Bergstrom | President, R&D | Sell | — | — |
| 2026-01-29 | Thomas Catinazzo | Chief Financial Officer | Sell | — | — |
| 2026-01-15 | Donald A Bergstrom | President, R&D | A | — | — |
| 2026-01-15 | Sanjiv Patel | President and CEO | A | — | — |
| 2026-01-15 | Peter Rahmer | See remarks | A | — | — |
| 2026-01-15 | Thomas Catinazzo | Chief Financial Officer | A | — | — |
| 2026-01-07 | Sanjiv Patel | President and CEO | MIXED | — | — |
| 2025-11-06 | LONNEL COATS | Director | A | — | — |
| 2025-11-06 | Habib J Dable | Director | A | — | — |
| 2025-11-04 | Sanjiv Patel | President and CEO | Sell | — | — |
| 2025-10-30 | Thomas Catinazzo | Chief Financial Officer | Sell | — | — |
| 2025-10-30 | Donald A Bergstrom | President, R&D | Sell | — | — |
| 2025-10-30 | Peter Rahmer | See remarks | Sell | — | — |
| 2025-07-30 | Thomas Catinazzo | Chief Financial Officer | Sell | — | — |
| 2025-07-30 | Brian Adams | Chief Legal Officer | Sell | — | — |
| 2025-07-30 | Peter Rahmer | See remarks | Sell | — | — |
| 2025-07-30 | Donald A Bergstrom | President, R&D | Sell | — | — |
| 2025-07-10 | Sanjiv Patel | President and CEO | Sell | — | — |
| 2025-07-01 | Peter Rahmer | See remarks | A | — | — |
| 2025-07-01 | Sanjiv Patel | President and CEO | A | — | — |
| 2025-06-11 | Claire Mazumdar | Director | A | — | — |
| 2025-06-06 | Alexis Borisy | Director | A | — | — |
| 2025-06-06 | Jami Rubin | Director | A | — | — |
| 2025-06-06 | Mark Murcko | Director | A | — | — |
| 2025-06-06 | LINDA A HILL | Director | A | — | — |
| 2025-06-06 | Sekar Kathiresan | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 21,904,963 | — |
| — | 10%+ Owner | 13,362,312 | — |
| — | 10%+ Owner | 12,799,078 | — |
| — | 10%+ Owner | 9,767,382 | — |
| — | 10%+ Owner | 3,281,253 | — |
| — | Director | 996,952 | — |
| — | 10%+ Owner | 968,365 | — |
| — | President and CEO | 767,247 | — |
| — | President, R&D | 407,660 | — |
| — | Chief Legal Officer | 389,748 | — |
| — | Director | 234,175 | — |
| — | See remarks | 223,657 | — |
| — | Chief Financial Officer | 140,568 | — |
| — | Director | 67,242 | — |
| — | Chief Administrative Officer | 45,164 | — |
| — | Director | 40,000 | — |
| — | Director | 25,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RLAY quote page; the site-wide leaderboard is on the insider transactions hub.